Scandion Oncology A/S (SCOL.ST)
- Previous Close
0.0188 - Open
0.0168 - Bid 0.0154 x --
- Ask 0.0167 x --
- Day's Range
0.0138 - 0.0168 - 52 Week Range
0.0050 - 1.5600 - Volume
4,073,631 - Avg. Volume
7,891,487 - Market Cap (intraday)
3.827M - Beta (5Y Monthly) 2.13
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2300 - Earnings Date May 22, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.26
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.
www.scandiononcology.comRecent News: SCOL.ST
View MorePerformance Overview: SCOL.ST
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SCOL.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SCOL.ST
View MoreValuation Measures
Market Cap
4.41M
Enterprise Value
-14.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-97.34%
Return on Equity (ttm)
-186.13%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-36.66M
Diluted EPS (ttm)
-0.2300
Balance Sheet and Cash Flow
Total Cash (mrq)
12.69M
Total Debt/Equity (mrq)
0.80%
Levered Free Cash Flow (ttm)
-16.58M